BioForward, Inc.’s Post

We’re excited to kick off 2025 at 𝐉𝐏 𝐌𝐨𝐫𝐠𝐚𝐧 𝐖𝐞𝐞𝐤 in San Francisco, January 13–16. Our CEO/CFO Peter Llewellyn-Davies and CMSO Dr. Romana Gugenberger will be sharing updates on our innovative oncology pipeline, including developments in #glioblastoma in collaboration with Dana-Farber Cancer Institute:   💊 INV501 – A small molecule that can activate anti-tumor immune responses and has shown promising preclinical results in several solid tumor models. 🧫 INV441 – A TIL-based cell therapy from our proprietary EPiC platform that is advancing towards clinical development in glioblastoma.   🔹 𝐌𝐞𝐞𝐭 𝐮𝐬 𝐭𝐡𝐞𝐫𝐞: Our management team is available for one-on-one meetings at Biotech Showcase and through the BIO partnering platform. Request a meeting via partneringOne or contact us directly at [email protected].   Find out more about our participation and progress in our latest update: https://lnkd.in/dCXuH4xk   #JPMWeek2025 #BiotechShowcase

Syncromune®, a Florida-based cancer biotechnology company, has successfully raised $100 million in a #SeriesA funding round. This investment will support the advancement of their innovative in situ immunotherapy platform, SYNC-T, designed to treat solid tumor cancers by combining partial oncolysis with a multi-target biologic drug infusion. The funding round was led by undisclosed investors, reflecting strong confidence in Syncromune's approach to personalized cancer treatment. The company plans to utilize the funds to accelerate clinical trials and further develop their proprietary technology, aiming to provide new therapeutic options for patients with metastatic castrate-resistant prostate cancer (mCRPC). Syncromune's CEO, Eamonn Hobbs, expressed enthusiasm about the investment, stating that it will enable the company to "rapidly advance our clinical programs and bring our innovative therapies to patients in need." The company's SYNC-T platform has recently received FDA Fast-Track Designation for its potential in treating mCRPC, underscoring the promise of their therapeutic approach. #Biotech #HealthcareInnovation #PrecisionMedicine #CancerResearch #Immunotherapy

Did you know that fewer than 10% of new cancer drugs make it from the lab to market? The key to overcoming this challenge lies in using the right models for drug development. At MIMETAS, we're redefining cancer drug discovery with our advanced 3D cancer models that accurately replicate human tumor environments. By providing predictive insights, we help bridge the critical gap between preclinical research and clinical success. Discover how our Oncology Services can accelerate your path to breakthrough therapies: https://lnkd.in/gfMUxACw #CancerResearch #CancerTherapies #DrugDiscovery #DrugDevelopment #Oncology

IOS-1002 is a multi-functional agent based on a naturally occurring human leukocyte antigen that targets multiple immune checkpoints ( LILRB1 (ILT2), LILRB2 (ILT4) and KIR3DL1) to activate both innate and adaptive immune cells. IOS-1002 (formerly iosH2) is described as an open format (peptide free conformation) and expression- and stability-optimized HLA-B57-B2m-IgG4_Fc fusion protein.

Delve into the molecular intricacies of cancer with DRUG-seq, an affordable and efficient RNA-seq application that is changing the landscape of oncology drug discovery. This state-of-the-art technology drives innovation in investigating mechanisms of drug action, profiling drug responses, discovering biomarkers, and untangling tumor heterogeneity. Contact us to find out how you can use Champions' new DRUG-seq platform to generate fast insights in drug discovery: https://hubs.li/Q02HsjHk0 #DRUGseq #OncologyResearch #CancerResearch #RNAseq #MechanismOfAction #DrugResponse #DrugResistance #BiomarkerDiscovery #TumorHeterogeneity #Oncology #Cancer #PrecisionMedicine #DrugDiscovery #endpointspotlight

Designing surface-bioengineered extracellular vesicles to target lung cancer cells: in their latest work, Ireneusz P. Grudzinski and Anna M. Nowicka at University of Warsaw and collaborators bioengineered extracellular vesicles from lung cancer cells, decorating them with the heptapeptide PTHTRWA, the most effective peptide for binding to lung cancer cells. https://lnkd.in/eHukjPtd Preclinical safety assays revealed no cytotoxic or genotoxic effects of these novel bioconstructs, though impedance-based studies indicated some transient impacts on endothelial barrier integrity. An article co-authored by Agata Kowalczyk, Damian Dziubak, Artur Kasprzak, Kamil Sobczak, Monika Rużycka, Magdalena Bamburowicz-Klimkowska, Slawomir Sek, Ivan Rios Mondragon, Teresa Żołek, Elise Rundén Pran, Sergey Shaposhnikov, Mihaela Roxana C. and Maria Dusinska #extracellularvesicles #exosomes #bioengineering #lungcancer #clickchemistry #Vesiculab

Innovative cancer research in focus Cancervax Corporation has chosen Pancreatic Ductal Adenocarcinoma (PDAC)—a notoriously hard-to-treat cancer—as a key focus for preclinical development. Their novel UCT Platform is a customizable technology designed to target a range of cancers. With a single injection delivering billions of nanoparticles, CancerVax is working toward new hope for patients facing this difficult disease. Learn more: 👉 https://lnkd.in/gTWBF7ve #CancerResearch #CancerTreatment #PancreaticCancer #Nanotechnology #UtahLifeSciences

𝐂𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞 𝐓𝐨 https://lnkd.in/euN7Z8i8 𝐠𝐞𝐭 𝐰𝐞𝐥𝐥-𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 The Mexico Antibody Drug Conjugates (ADC) Market is paving the way for groundbreaking advancements in oncology. Combining the precision of antibodies with the potency of cytotoxic drugs, ADCs are redefining cancer treatment by targeting cancer cells while sparing healthy tissue. With increasing investments in biotech R&D and growing adoption of personalized medicine, Mexico is emerging as a key player in the ADC landscape. 🚀 The future of oncology is here—focused, effective, and life-changing. To Get more:https://lnkd.in/dCyCfKzM #AntibodyDrugConjugates #OncologyInnovation #BiotechMexico #TargetedTherapies #PharmaTrends"

💡 Biotech Update! 💡 At the recent ASCO conference, the spotlight was on the potential of Antibody-Drug Conjugates (ADCs) to replace traditional chemotherapy. 🧬✨ These next-gen treatments are designed to deliver targeted therapy with fewer side effects, promising a new era in cancer care. In parallel, AbbVie is making strategic moves to rebuild its portfolio following the Rova-T setback. The focus is now on developing innovative assets that harness the power of ADCs, aiming to revolutionize oncology treatment and improve patient outcomes. Stay tuned as we witness the evolution of cancer therapy and the advancements that could redefine the standard of care. #ASCO #Biotech #CancerResearch #ADCs #Oncology #AbbVie #HealthcareInnovation #NextGenTherapeutics #CancerTreatment 🌐🔬

Cancer claims over 10 million lives annually, underscoring the urgent need for more effective treatments. However, the transition from lab to clinic is hindered by models that poorly reflect the complexity of human tumors, with just 5% of new cancer drugs succeeding in the market. Using our OrganoCore™ Discovery Platform, MIMETAS captures the tumor microenvironment with unprecedented accuracy, delivering advanced 3D cancer models that support: - Early Drug Discovery: Compound validation and early testing - Lead Candidate Selection: Detailed ADME-tox testing and optimization - Project Scalability: Flexible, fee-for-service solutions that adapt to your project needs and timelines 🌐 Visit our Oncology Services page to learn more about our capabilities and how we can support your projects in combating cancer: https://lnkd.in/eBwzzZtj #CancerResearch #Oncology #OncologyResearch #Innovation